User profiles for SHIVAANI KUMMAR

Shivaani Kummar

Professor of Medicine, OHSU
Verified email at ohsu.edu
Cited by 15141

[HTML][HTML] Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

A Drilon, TW Laetsch, S Kummar… - … England Journal of …, 2018 - Mass Medical Soc
Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a …

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

DS Hong, SG DuBois, S Kummar, AF Farago… - The Lancet …, 2020 - thelancet.com
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult
patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of …

Nirogacestat, a γ-secretase inhibitor for desmoid tumors

…, T Philip, JG Pressey, S Kummar… - … England Journal of …, 2023 - Mass Medical Soc
Background Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors
without approved treatments. Methods We conducted a phase 3, international, double-blind, …

[HTML][HTML] Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

S Kummar, R Kinders, ME Gutierrez… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose We conducted the first phase 0 clinical trial in oncology of a therapeutic agent
under the Exploratory Investigational New Drug Guidance of the US Food and Drug …

[HTML][HTML] Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors

…, AP Chen, JH Doroshow, S Kummar - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Wee1 tyrosine kinase phosphorylates and inactivates cyclin-dependent kinase (Cdk)
1/2 in response to DNA damage. AZD1775 is a first-in-class inhibitor of Wee1 kinase with …

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames… - Cancer research, 2011 - AACR
A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a
topoisomerase I–targeted agent, was carried out to determine maximum tolerated dose (MTD), …

Wee1 kinase as a target for cancer therapy

K Do, JH Doroshow, S Kummar - Cell cycle, 2013 - Taylor & Francis
Wee1, a protein kinase, regulates the G 2 checkpoint in response to DNA damage. Preclinical
studies have elucidated the role of wee1 in DNA damage repair and the stabilization of …

SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study

A Ribas, T Medina, S Kummar, A Amin, A Kalbasi… - Cancer discovery, 2018 - AACR
PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been
observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide …

Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer

…, MD Hellmann, DR Shepard, BI Rini, S Kummar… - Cancer discovery, 2020 - AACR
This first-in-human study of an A2AR antagonist for cancer treatment establishes the safety
and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent …

Compressing drug development timelines in oncology using phase'0'trials

S Kummar, R Kinders, L Rubinstein… - Nature Reviews …, 2007 - nature.com
The optimal evaluation of molecularly targeted anticancer agents requires the integration of
pharmacodynamic assays into early clinical investigations. Phase '0' trials conducted under …